Home › Funds › Propel Bio Management, LLC › OVID

Propel Bio Management, LLC position in OVID

OVID THERAPEUTICS INC · Health Care

Propel Bio Management, LLC reported holding 1,018,721 shares of OVID (OVID THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.5M, representing 1.34% of its reported portfolio and ranking #24 among its reported holdings. Propel Bio Management, LLC has disclosed OVID holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)1.02M sh
Reported value held$2.54M
Portfolio Weight1.34%
First reportedQ1 2026
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Propel Bio Management, LLC's OVID position evolved

Propel Bio Management, LLC first disclosed a stake in OVID in Q1 2026 at 921,457 shares (US$2.0M). The position peaked in Q2 2026 at 1,115,538 shares, worth US$3.0M. Across 3 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,018,721 shares valued at US$2.5M — a reduction of -96,817 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 921.46K $2.04M New
Q2 2026 1.12M $3.00M Add
Q3 2026 1.02M $2.54M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OVID and 13F data

OVID (OVID THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in OVID — the largest reported positions include Affinity Asset Advisors, LLC (US$27.3M), ADAR1 Capital Management, LLC (US$20.0M), SILVERARC CAPITAL MANAGEMENT, LLC (US$14.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OVID

All OVID fund holders →

FAQ

How long has Propel Bio Management, LLC held OVID?

Propel Bio Management, LLC has disclosed OVID holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Propel Bio Management, LLC's current position in OVID?

As of Q3 2026, Propel Bio Management, LLC holds 1.02M shares of OVID (OVID THERAPEUTICS INC), valued at $2.54M, representing 1.34% of its reported portfolio and ranking #24.

Has Propel Bio Management, LLC been buying or selling OVID?

In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in OVID. The position peaked in Q2 2026 at 1.12M shares.

Which other funds hold OVID?

Other major institutional holders of OVID include Affinity Asset Advisors, LLC, ADAR1 Capital Management, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.